Ruxolitinib, Free base | 2139

Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC₅₀'s of 2.7 and 4.5 nM for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis.

Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC₅₀'s of 2.7 and 4.5 nM for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis.

2139 | Ruxolitinib, Free base DataSheet

Alternate Name/Synonyms: INCB018424; INC18424; NCB018424; NCB18424

Appearance: Off-white solid

Formulation: N/A

CAS Number: 941678-49-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₇H₁₈N₆

Molecular Weight: 306.37

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (25 mg/ml) or EtOH (~ 15 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent JAK inhibitor

MDL Number: MFCD12031592

PubChem CID: 25126798

SMILES: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

InChi: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

InChi Key: HFNKQEVNSGCOJV-OAHLLOKOSA-N